Use your antibodies-online credentials, if available.
抗Rat (Rattus) 抗体:
抗Mouse (Murine) 抗体:
Human Polyclonal SMARCA4 Primary Antibody for ChIP, ICC - ABIN4285245
Miyamoto, Pasque, Jullien, Gurdon: Nuclear actin polymerization is required for transcriptional reprogramming of Oct4 by oocytes. in Genes & development 2011
Show all 4 Pubmed References
Human Monoclonal SMARCA4 Primary Antibody for ICC, IF - ABIN2668498
de la Serna, Ohkawa, Higashi, Dutta, Osias, Kommajosyula, Tachibana, Imbalzano: The microphthalmia-associated transcription factor requires SWI/SNF enzymes to activate melanocyte-specific genes. in The Journal of biological chemistry 2006
Human Monoclonal SMARCA4 Primary Antibody for ICC, IF - ABIN2668499
Ohkawa, Harada, Nakamura, Yoshimura, Tachibana: Production of a rat monoclonal antibody against Brg1. in Hybridoma (2005) 2009
Human Polyclonal SMARCA4 Primary Antibody for WB - ABIN686122
Chen, Han, Wei, Zhang, Shi, Duan, Li, Zhou, Pu, Zhang, Kang: SNORD76, a box C/D snoRNA, acts as a tumor suppressor in glioblastoma. in Scientific reports 2015
IGF1R (显示 IGF1R 抗体) phosphorylates histone H3 (显示 HIST3H3 抗体) at tyrosine 41 and has a role in inducing SNAI2 expression in a process that involves Brg1 chromatin remodeling protein
Loss of BRG1 is associated with the loss of E-cadherin (显示 CDH1 抗体) and up-regulation of Vimentin (显示 VIM 抗体) in primary tumors, which explains why BRG1 loss is associated with a poor prognosis in multiple tumor types.
Low expression of SMARCA4/BRG1 is significantly associated with worse prognosis.
Taken together, these findings provide a dynamic view of SMARCA4-dependent changes in higher-order chromatin organization and gene expression, identifying SMARCA4 as a novel component of chromatin organization.
Of the 34 undifferentiated endometrial carcinomas examined, 17 (50%) exhibited SWI (显示 SMARCA1 抗体)/SNF (显示 SNRPA 抗体) complex inactivation, with 11 tumors showing complete loss of both ARID1A (显示 ARID1A 抗体) and ARID1B (显示 ARID1B 抗体), 5 showing complete loss of BRG1 and 1 showing complete loss of INI1 (显示 SMARCB1 抗体). Ten of the remaining 17 undifferentiated carcinomas showed the following alterations: 5 tumors (15%) showed loss of ARID1A (显示 ARID1A 抗体) only with intact ARID1B (显示 ARID1B 抗体), BRG1, and INI1 (显示 SMARCB1 抗体) expression.
Data suggest that the BRG1/STAT3 (显示 STAT3 抗体)/VEGFC (显示 VEGFC 抗体) in tumor-associated lymphangiogenesis might lead to the discovery of novel therapeutic targets in the treatment of cancers with BRG1 loss of function.
Results suggest that targeting the enzymatic activity of BRG1 would be an effective adjuvant therapy for breast cancer.
The vast majority of SCCOHT demonstrate genomic SMARCA4 loss with only rare co-occurring alterations. Data support a role for CGP in the diagnosis and management of SCCOHT and of other lesions with overlapping histological and clinical features, since identifying the former by genomic profile suggests benefit from an appropriate regimen and treatment decisions.
BRG1 can promote VEGF-A (显示 VEGFA 抗体) expression and angiogenesis in colorectal cancer and BRG1 may be a novel drug target for the treatment of colorectal cancer.
The BRG1/SIRT1 (显示 SIRT1 抗体)/p53 (显示 TP53 抗体) signal axis is a novel mechanism of cell senescence in CRC (显示 CALR 抗体).
Chromatin accessibility at OCT4 (显示 POU5F1 抗体)-bound sites requires the chromatin remodeller BRG1, which is recruited to these sites by OCT4 (显示 POU5F1 抗体) to support additional transcription factor binding and expression of the pluripotency-associated transcriptome.
Data (including data from studies using knockout mice) suggest that Brg1 is phosphorylated by casein kinase 2 (Ck2 (显示 CSNK2A1 抗体); Ck2alpha1 and Ck2alpha-prime are catalytic subunits) in proliferating skeletal myoblasts; Brg1 is catalytic subunit of SWI (显示 SMARCA1 抗体)/SNF (显示 SNRPA 抗体) chromatin-remodeling enzymes; Ck2 (显示 CSNK2A1 抗体)-mediated phosphorylation of Brg1 appears to regulate myoblast proliferation. (Brg1 = Brahma (显示 SMARCA2 抗体)-related gene 1 protein)
BRG1 is a SOX10 (显示 SOX10 抗体) co-activator, required to establish the melanocyte lineage and promote expression of genes important for melanocyte function.
n keratinocytes, the promoter-enhancer anchoring regions in the gene-rich transcriptionally active TADs are enriched for the binding of chromatin architectural proteins CTCF (显示 CTCF 抗体), Rad21 (显示 RAD21 抗体) and chromatin remodeler Brg1. In contrast to gene-rich TADs, gene-poor TADs show preferential spatial contacts with each other, do not contain active enhancers and show decreased binding of CTCF (显示 CTCF 抗体), Rad21 (显示 RAD21 抗体) and Brg1 in keratinocytes
Data demonstrate that Brg1 plays an essential role in development and homeostasis, including morphogenesis, stem cell differentiation and cell survival in the duodenum.
Point mutations in SMARCA4 (also known as BRG1) mapping to the ATPase (显示 DNAH8 抗体) domain cause loss of direct binding between BAF (显示 BANF1 抗体) and PRC1 (显示 PRC1 抗体).
BRG1 promotes transcription of endothelial Mrtfa and Mrtfb, which elevates expression of SRF and SRF target genes that establish embryonic capillary integrity.
RB is necessary for the recruitment of the BRG1 ATPase (显示 DNAH8 抗体) to DNA double-strand breaks, which stimulates DNA end resection and homologous recombination
Cdx (显示 CDX1 抗体) members interact with the SWI (显示 SMARCA1 抗体)-SNF (显示 SNRPA 抗体) complex and make direct contact with Brg1, a catalytic member of SWI (显示 SMARCA1 抗体)-SNF (显示 SNRPA 抗体). Both Cdx2 (显示 CDX2 抗体) and Brg1 co-occupy a number of Cdx (显示 CDX1 抗体) target genes, and both factors are necessary for transcriptional regulation of such targets. Finally, Cdx2 (显示 CDX2 抗体) and Brg1 occupancy occurs coincident with chromatin remodeling at some of these loci.
BRG1/BRM (显示 SMARCA2 抗体) and c-MYC (显示 MYC 抗体) have an antagonistic relationship regulating the expression of cardiac conduction genes that maintain contractility, which is reminiscent of their antagonistic roles as a tumor suppressor and oncogene (显示 RAB1A 抗体) in cancer.
The protein encoded by this gene is a member of the SWI/SNF family of proteins and is similar to the brahma protein of Drosophila. Members of this family have helicase and ATPase activities and are thought to regulate transcription of certain genes by altering the chromatin structure around those genes. The encoded protein is part of the large ATP-dependent chromatin remodeling complex SNF/SWI, which is required for transcriptional activation of genes normally repressed by chromatin. In addition, this protein can bind BRCA1, as well as regulate the expression of the tumorigenic protein CD44. Mutations in this gene cause rhabdoid tumor predisposition syndrome type 2. Multiple transcript variants encoding different isoforms have been found for this gene.
SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 4
, SWI/SNF-related matrix-associated actin-dependent regulator of chromatin a4
, transcription activator BRG1-like
, ATP-dependent helicase SMARCA4
, BRG1-associated factor 190A
, BRM/SWI2-related gene 1
, SNF2-like 4
, brahma protein-like 1
, global transcription activator homologous sequence
, homeotic gene regulator
, mitotic growth and transcription activator
, nuclear protein GRB1
, protein BRG-1
, protein brahma homolog 1
, sucrose nonfermenting-like 4
, transcription activator BRG1
, SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily A member 4
, SWI/SNF related transcriptional activator
, WI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 4